Article

Blincyto Leads to High MRD Response in B-Precursor ALL

At least 80 percent of patients with B-precursor acute lymphoblastic leukemia had a complete minimal residual disease response after a single cycle of treatment with Blincyto (blinatumomab).

At least 80 percent of patients with B-precursor acute lymphoblastic leukemia (ALL) had a complete minimal residual disease (MRD) response after a single cycle of treatment with Blincyto (blinatumomab). The study results of the CD19-directed antibody was unveiled at the 2014 American Society of Hematology (ASH) annual meeting.

On December 3, 2014, the FDA granted an accelerated approval to Blincyto as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor ALL, based on findings from the full cohort of patients in the phase 2 trial. The approval came five months early, based on the Food and Drug Administration’s expected review timeline for the drug. (Read more.)

In the phase 2 study reported at ASH, 103 patients were evaluable for complete MRD response, with 82 participants meeting the response criteria after one cycle of Blincyto, a bi-specific T-cell engager (BiTE) antibody construct. Blincyto’s anticancer activity comes from its ability to direct cytotoxic T-cells to CD19-positive cells, leading to serial lysis. CD19 is a highly specific B-cell marker and is expressed in more than 90 percent of B-cell malignancies.

An analysis that included all 112 patients who received at least one cycle of Blincyto showed that 88 patients (78 percent) met response criteria. An exploratory analysis of MRD response (as opposed to complete MRD response) showed that 96 patients met the criteria, including 82 in the primary efficacy analysis.

“Most patients achieved a complete MRD response within one cycle of treatment,” said Nicola Gokbuget, a hematologic oncologist at Goethe University Hospital in Frankfurt, Germany. “Responses occurred in all subgroups, including older patients and patients with high MRD levels.”

No predictive factor for MRD response was identified. The most common side effects reported were flu-like symptoms associated with T-cell activation.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Related Content